Kalaris Therapeutics Inc (KLRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -58,769 | -190,418 | -168,710 | -171,962 | -69,784 |
| Depreciation Amortization | N/A | 398 | 723 | 189 | 73 |
| Accounts receivable | 206 | -49 | -107 | N/A | N/A |
| Accounts payable and accrued liabilities | -28,862 | -2,512 | -12,622 | 20,290 | 2,726 |
| Other Working Capital | -25,305 | 2,025 | -16,146 | 19,354 | -1,031 |
| Other Operating Activity | 45,025 | 66,105 | 54,810 | 25,810 | 7,205 |
| Operating Cash Flow | $-67,705 | $-124,451 | $-142,052 | $-106,319 | $-60,811 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 95,000 | 37,985 | -80,478 | 186,009 | -169,262 |
| PPE Investments | N/A | N/A | N/A | -26 | -235 |
| Investing Cash Flow | $95,000 | $37,985 | $-80,478 | $185,983 | $-169,497 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 21 | 70,495 | 126,961 | 232 | 295,449 |
| Other Financing Activity | 0 | 0 | 0 | 0 | -3,474 |
| Financing Cash Flow | $21 | $70,495 | $126,961 | $232 | $291,975 |
| Exchange Rate Effect | N/A | N/A | N/A | -44 | -90 |
| Beginning Cash Position | 90,973 | 106,944 | 202,513 | 122,661 | 61,084 |
| End Cash Position | 118,289 | 90,973 | 106,944 | 202,513 | 122,661 |
| Net Cash Flow | $27,316 | $-15,971 | $-95,569 | $79,852 | $61,577 |
| Free Cash Flow | |||||
| Operating Cash Flow | -67,705 | -124,451 | -142,052 | -106,319 | -60,811 |
| Capital Expenditure | N/A | N/A | N/A | -26 | -235 |
| Free Cash Flow | -67,705 | -124,451 | -142,052 | -106,345 | -61,046 |